Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study
David Qualls, Nicholas Lambert, Paolo F. Caimi, Mwanasha H. Merrill, Priyanka Pullarkat, Richard Godby, David A. Bond, Graham T. Wehmeyer, Jason T. Romancik, Behzad Amoozgar, Lori A. Leslie, Loretta J. Nastoupil, Jennifer L. Crombie, Jeremy S. Abramson, Arushi Khurana, Grzegorz S. Nowakowski, Kami J. Maddocks, Sarah C. Rutherford, Brad S. Kahl, Michelle Okwali, Michael J. Buege, Venkatraman Seshan, Connie Lee Batlevi, Gilles Salles
Abstract
ABSTRACT: In this real-world evaluation of tafasitamab-lenalidomide (TL) in relapsed or refractory LBCL, patients receiving TL had higher rates of comorbidities and high-risk disease characteristics, and substantially lower progression-free survival and overall survival, compared with the L-MIND registration clinical trial for TL.